Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases - PubMed (original) (raw)
Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases
J Wu et al. Jpn J Cancer Res. 2001 Apr.
Abstract
Peroxynitrite (ONOO(-)), which is generated from nitric oxide (NO) and superoxide anion (O(2)(.-)) under pathological conditions, plays an important role in pathophysiological processes. Activation of matrix metalloproteinases (MMPs) contributes to tumor angiogenesis and metastasis. NO mediates the enhanced vascular permeability and retention (EPR) effect in solid tumors, and ONOO(-)activates proMMP to MMP in vitro. In this study, we examined the role of ONOO(-)in the EPR effect in solid tumors and normal tissues as related to MMP activation. Authentic ONOO(-), at 50 nmol or higher concentrations, induced the enhanced vascular permeability in normal dorsal skin of mice. ONOO(-)scavengers ebselen and uric acid significantly suppressed the EPR effect in mouse sarcoma 180 (S-180) tumors. Indirect evidence for formation of ONOO(-)in S-180 and mouse colon adenocarcinoma (C-38) tumors included strong immunostaining for nitrotyrosine in the tumor tissue, predominantly surrounding the tumor vessels. MMP inhibitor BE16627B (66.6 mg / kg i.v., given 2 times) or SI-27 (10 mg / kg i.p., given 2 times) significantly suppressed the ONOO(-)-induced EPR effect in S-180 tumors and in normal skin. Soybean trypsin inhibitor (Kunitz type), broad-spectrum proteinase inhibitor ovomacroglobulin, and bradykinin receptor antagonist HOE 140 also significantly suppressed the ONOO(-)-induced EPR effect in normal skin tissues. These data suggest that ONOO(-)may be involved in and promote the EPR effect in tumors, which could be mediated partly through activation of MMPs and a subsequent proteinase cascade to generate potent vasoactive mediators such as bradykinin.
Similar articles
- (-)-Epicatechin 3-O-gallate ameliorates the damages related to peroxynitrite production by mechanisms distinct from those of other free radical inhibitors.
Yokozawa T, Rhyu DY, Cho EJ. Yokozawa T, et al. J Pharm Pharmacol. 2004 Feb;56(2):231-9. doi: 10.1211/0022357022601. J Pharm Pharmacol. 2004. PMID: 15005882 - Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine.
Iki K, Tsutsumi M, Kido A, Sakitani H, Takahama M, Yoshimoto M, Motoyama M, Tatsumi K, Tsunoda T, Konishi Y. Iki K, et al. Carcinogenesis. 1999 Jul;20(7):1323-9. doi: 10.1093/carcin/20.7.1323. Carcinogenesis. 1999. PMID: 10383907 - Kallikrein-kinin in infection and cancer.
Maeda H, Wu J, Okamoto T, Maruo K, Akaike T. Maeda H, et al. Immunopharmacology. 1999 Sep;43(2-3):115-28. doi: 10.1016/s0162-3109(99)00104-6. Immunopharmacology. 1999. PMID: 10596842 Review. - Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
Maeda H, Fang J, Inutsuka T, Kitamoto Y. Maeda H, et al. Int Immunopharmacol. 2003 Mar;3(3):319-28. doi: 10.1016/S1567-5769(02)00271-0. Int Immunopharmacol. 2003. PMID: 12639809 Review.
Cited by
- Magnetoliposomes with Calcium-Doped Magnesium Ferrites Anchored in the Lipid Surface for Enhanced DOX Release.
Cardoso BD, Fernandes DEM, Amorim CO, Amaral VS, Coutinho PJG, Rodrigues ARO, Castanheira EMS. Cardoso BD, et al. Nanomaterials (Basel). 2023 Sep 20;13(18):2597. doi: 10.3390/nano13182597. Nanomaterials (Basel). 2023. PMID: 37764626 Free PMC article. - Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
Kim J, Cho H, Lim DK, Joo MK, Kim K. Kim J, et al. Int J Mol Sci. 2023 Jun 13;24(12):10082. doi: 10.3390/ijms241210082. Int J Mol Sci. 2023. PMID: 37373227 Free PMC article. Review. - Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.
Goel M, Mackeyev Y, Krishnan S. Goel M, et al. Cancer Nanotechnol. 2023;14(1):15. doi: 10.1186/s12645-023-00165-y. Epub 2023 Feb 27. Cancer Nanotechnol. 2023. PMID: 36865684 Free PMC article. Review. - Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.
Rasel MSI, Mohona FA, Akter W, Kabir S, Chowdhury AA, Chowdhury JA, Hassan MA, Al Mamun A, Ghose DK, Ahmad Z, Khan FS, Bari MF, Rahman MS, Amran MS. Rasel MSI, et al. J Oncol. 2022 Sep 29;2022:9396760. doi: 10.1155/2022/9396760. eCollection 2022. J Oncol. 2022. PMID: 36284633 Free PMC article. Review. - Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol.
Zielińska A, Cano A, Andreani T, Martins-Gomes C, Silva AM, Szalata M, Słomski R, Souto EB. Zielińska A, et al. Int J Mol Sci. 2022 May 31;23(11):6165. doi: 10.3390/ijms23116165. Int J Mol Sci. 2022. PMID: 35682847 Free PMC article. Review.
References
- Matsumura , Y. . and Maeda , H.A new concept for macro‐molecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS . Cancer Res. , 46 , 6387 – 6392 ( 1986. ). - PubMed
- Maeda , H.SMANCS and polymer‐conjugated macromolecular drugs: advantages in cancer chemotherapy . Adv. Drug Delivery Rev. , 6 , 181 – 202 ( 1991. ). - PubMed
- Maeda , H.Polymer conjugated macromolecular drugs for tumor‐specific targeting . In “ Polymeric Site‐specific Pharmacotherapy ,” ed. Domb A. J. , pp . 96 – 116 ( 1994. ). John Wiley & Sons Ltd. , New York .
- Duncan , R. , Connors , T. A. . and Maeda , H.Drug targeting in cancer therapy: the magic bullet, what next ? J. Drug Targeting , 3 , 317 – 319 ( 1996. ). - PubMed
- Muggia , F. M.Doxorubicin‐polymer conjugates: further demonstration of the concept of enhanced permeability and retention . Clin. Cancer Res. , 5 , 7 – 8 ( 1991. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources